Novo Nordisk ® dence of semaglutide to further ronic disease clinical evidence underlining obesity as a serious chronic disease ASIS trials erior weight utide vs le with EF trial erior KCCQ-CSS vs SELECT CVOT trial SELECT is the largest trial ever completed by Novo Nordisk, including >17,500 participants across more than 800 sites in 41 countries Semaglutide 2.4 mg could become the first and only AOM with a proven CV risk reduction for people with obesity and established CVD 6 Obesity-Associated Disorders (OBAD). Massachusetts General Hospital & George Washington University. [Poster presentation] mmary score, CVD: Cardiovascular disease; HFpEF: Heart Failure with preserved ejection fraction; CVOT: Cardiovascular outcomes trial;
Download PDF file